Updated: January 29, 2021
We recognize that this may be a challenging and stressful time, especially if you are a patient managing a serious illness. As the COVID-19 global pandemic continues to evolve, we are committed to doing everything we can to deliver for patients, to keep our staff and their families safe, and to help the communities where we live and work reduce the number of people exposed to the virus.
Amgen’s COVID-19 Priorities
- Ensuring the safety and well-being of our 23,000+ Amgen employees around the world
- Continuing to serve patients – those currently on Amgen medicines and those that stand to benefit from potential new medicines in our pipeline
- Contributing our therapeutic antibody and immunology expertise to the fight against COVID-19
- Lending a helping hand in the communities where we live and work
PRESS RELEASE 10.26.2020Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial